A comparison of ELT and SLT

Article

A study by Italian researchers, the results of which have been published online by Eye, has found that both excimer laser trabeculotomy (ELT) and selective laser trabeculoplasty (SLT) are both equally effective treatment options for primary open angle glaucoma.

A study by Italian researchers, the results of which have been published online by Eye, has found that both excimer laser trabeculotomy (ELT) and selective laser trabeculoplasty (SLT) are both equally effective treatment options for primary open angle glaucoma (POAG) refractory to medical therapy.

Silvia Babighian and colleagues from St Antonio Hospital in Padova, Italy sought to compare the safety and efficacy of ELT and SLT as a treatment for patients with POAG over a 24 month follow-up period. The prospective, randomized study consisted of 30 consecutive eyes assigned randomly to receive either of the treatments. ELT was performed with the XeCl excimer laser with an emission wavelength of 308 nm, with eight laser spots equally distributed over the anterior trabeculum. The SLT procedures were carried out with a frequency doubled q-switched neodymium : yytrium-aluminum-garnet laser. Approximately 50 adjacent laser spots were distributed over 180° of the trabecular meshwork. Procedure success was defined as a ≥20% reduction in IOP.

After 24 months, success in the ELT group was 53.3% and 40% in the SLT group. Mean IOP decreased 25.0±1.9 to 17.6±2.2 mmHg and from 23.9±0.9 to 19.1±1.8 mmHg in the ELT and SLT groups, respectively.

Babighian and colleagues were able to conclude that both techniques are effective in treating POAG.

Click here for full abstract.

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.